gov winter plan14 Sep 2021 15:17
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1017404/COVID-19-response-autumn-and-winter-plan-2021.pdf
Antivirals and therapeutics
21. Advances in antivirals and therapeutics will continue to provide additional tools to
manage COVID-19. Several treatments are already available through the NHS for
patients with COVID-19, including dexamethasone and tocilizumab which reduce
morbidity and mortality.
22. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently
approved casirivimab and imdevimab as the first monoclonal antibody combination
product indicated for use in the prevention and treatment of acute COVID-19 infection
for the UK in some individuals.16 The Government is now working with the NHS and
expert clinicians to ensure this treatment can be rolled out to NHS patients as soon
as possible.
23. In April, the Prime Minister launched the Antivirals Taskforce. The aim of the Taskforce
is to identify treatments for UK patients who have been exposed to COVID-19 to stop
the infection spreading and speed up recovery time. The Taskforce is leading the
search for new antivirals, which disrupt how the virus replicates in the body and can
reduce the number of patients who are hospitalised, and potentially help to break
chains of transmission when administered responsibly.
15 Third primary COVID-19 vaccine dose for people who are immunosuppressed: JCVI advice 16 Press Release: Regulatory approval of ronapreve
COVID-19 RESPONSE: AUTUMN AND WINTER PLAN 9
24. The Government will continue to work with the life sciences sector to ensure that
effective therapeutics, including antivirals, complement the vaccination programme
to enable the long-term management of COVID-19 and its clinical impacts. The
Government and NHS will set out more details on the availability and administration
of further treatments in due course.
Sign In
Follow the stocks
